Clinical data presented today demonstrates the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback